Calibration of the Ph. Eur. human coagulation Factor VIII concentrate BRP batch 5.

Q4 Medicine
Pharmeuropa bio & scientific notes Pub Date : 2017-01-01
S Raut, A Costanzo, A Daas, K H Buchheit
{"title":"Calibration of the Ph. Eur. human coagulation Factor VIII concentrate BRP batch 5.","authors":"S Raut,&nbsp;A Costanzo,&nbsp;A Daas,&nbsp;K H Buchheit","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>The European Pharmacopoeia Biological Reference Preparation (Ph. Eur. BRP) for Factor VIII Concentrate batch 5 was established through a collaborative study involving 14 laboratories organised by the European Directorate for the Quality of Medicines & HealthCare (EDQM, Council of Europe) to be used as working standard for potency determination of human coagulation Factor VIII (FVIII) preparations. The potency of the BRP batch 5 was assigned with reference to the WHO 8<sup>th</sup> International Standard (IS) for FVIII Concentrate and the BRP batch 4. Participants were instructed to perform 3 independent Factor VIII potency assays following their own routine validated methods by the chromogenic assay as it is the assay prescribed by the European Pharmacopoeia. This publication reports the results obtained during the study. The consensus potency, 9.9 IU/ampoule (n = 14) when assessed against both standards, with inter-laboratory geometric coefficients of variation (GCV) of 3.2 % and 1.9 % against the WHO 8<sup>th</sup> IS and the BRP batch 4 respectively, was consistent with the expected value. The Ph. Eur. BRP batch 5 is a freeze-dried, plasma-derived concentrate. Based on accelerated degradation studies, the stability of the material is suitable as a reference preparation. The Ph. Eur. BRP batch 5 was adopted at the 151<sup>st</sup> session of the European Pharmacopoeia Commission in March 2015 and is available from the EDQM.</p>","PeriodicalId":39192,"journal":{"name":"Pharmeuropa bio & scientific notes","volume":"2017 ","pages":"1-11"},"PeriodicalIF":0.0000,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmeuropa bio & scientific notes","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

The European Pharmacopoeia Biological Reference Preparation (Ph. Eur. BRP) for Factor VIII Concentrate batch 5 was established through a collaborative study involving 14 laboratories organised by the European Directorate for the Quality of Medicines & HealthCare (EDQM, Council of Europe) to be used as working standard for potency determination of human coagulation Factor VIII (FVIII) preparations. The potency of the BRP batch 5 was assigned with reference to the WHO 8th International Standard (IS) for FVIII Concentrate and the BRP batch 4. Participants were instructed to perform 3 independent Factor VIII potency assays following their own routine validated methods by the chromogenic assay as it is the assay prescribed by the European Pharmacopoeia. This publication reports the results obtained during the study. The consensus potency, 9.9 IU/ampoule (n = 14) when assessed against both standards, with inter-laboratory geometric coefficients of variation (GCV) of 3.2 % and 1.9 % against the WHO 8th IS and the BRP batch 4 respectively, was consistent with the expected value. The Ph. Eur. BRP batch 5 is a freeze-dried, plasma-derived concentrate. Based on accelerated degradation studies, the stability of the material is suitable as a reference preparation. The Ph. Eur. BRP batch 5 was adopted at the 151st session of the European Pharmacopoeia Commission in March 2015 and is available from the EDQM.

校准Ph. Eur。人凝血因子VIII浓缩物BRP第5批。
欧洲药典生物参考制剂(Ph. Eur。第5批因子VIII浓缩物的BRP是由欧洲药品和保健质量理事会(EDQM,欧洲委员会)组织的一项涉及14个实验室的合作研究建立的,作为测定人凝血因子VIII (FVIII)制剂效价的工作标准。BRP第5批的效价参照世卫组织第八项FVIII浓缩物国际标准(IS)和BRP第4批进行分配。参与者被指示按照他们自己的常规验证方法进行3次独立的因子VIII效价测定,因为这是欧洲药典规定的测定方法。本出版物报道了研究期间获得的结果。当对两种标准进行评估时,共识效价为9.9 IU/安瓿(n = 14),实验室间几何变异系数(GCV)分别为WHO第8号IS和BRP第4批的3.2%和1.9%,与期望值一致。博士学位。BRP第5批是冻干血浆衍生浓缩物。基于加速降解研究,该材料的稳定性适合作为参考制剂。博士学位。BRP第5批于2015年3月在欧洲药典委员会第151次会议上通过,可从EDQM获得。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Pharmeuropa bio & scientific notes
Pharmeuropa bio & scientific notes Medicine-Medicine (all)
CiteScore
0.70
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信